Efficacy and Safety of Anlotinib As an Adjuvant Therapy in Hepatocellular Carcinoma Patients with a High Risk of Postoperative Recurrence

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2023 Sep 11

PMID 37691893

Authors

Jianguo Wang

Xiaonan Xiang

Zhixiong Shi

Hui Zhang

Quanbao Zhang

Zhikun Liu

Guangjie Zhao

Chuanxing Wu

Qiang Wei

Lin Zhong

Zhengxin Wang

Guoyue Lv

Shusen Zheng

Xiao Xu

Affiliations

Soon will be listed here.

Abstract

Objective: Hepatocellular carcinoma (HCC) has a high rate of postoperative recurrence and lacks an effective treatment to prevent recurrence. This study aims to investigate the efficacy and safety of anlotinib in postoperative adjuvant therapy for HCC patients with high-risk recurrence factors.

Methods: For this multicenter, retrospective study, we recruited 63 HCC patients who received either anlotinib (n=27) or transcatheter arterial chemoembolization (TACE) (n=36) from six research centers in China between March 2019 and October 2020. The primary endpoint was disease-free survival (DFS) and the secondary endpoints were overall survival (OS) and safety.

Results: In this study, the median follow-up time was 25.9 and 26.8 months in the anlotinib and TACE groups, respectively. There was no significant difference in the median DFS between the anlotinib [26.8 months, 95% confidence interval (95% CI): 6.8-NE] and TACE groups (20.6 months, 95% CI: 8.4-NE). The 12-month OS rates in the anlotinib and TACE groups were 96.3% and 97.2%, respectively. In the anlotinib group, 19 of 27 patients (70.4%) experienced treatment-emergent adverse events, with the most common events (≥10%) being hypertension (22.2%) and decreased platelet count (22.2%).

Conclusions: The results indicate that anlotinib, as a new, orally administered tyrosine kinase inhibitor, has the same efficacy as TACE, and side effects can be well controlled.

Citing Articles

Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.

Wang G, Wang Y, Jin C, Sun X Pharmacol Rep. 2025; .

PMID: 39899257 DOI: 10.1007/s43440-025-00700-1.

Efficacy and safety of transarterial chemoembolization alone compared to its combination with anlotinib among patients with intermediate or advanced stage hepatocellular carcinoma: a phase II randomized controlled trial.

Zhang D, Zhang Z, Luo J, Zheng J, Mao X, Tsilimigras D J Gastrointest Oncol. 2024; 15(4):1627-1635.

PMID: 39279973 PMC: 11399860. DOI: 10.21037/jgo-24-497.

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis.

Xie M, Huang Q, Gong T, Wang Y, Li Z, Lu M Front Oncol. 2024; 14:1399574.

PMID: 38807768 PMC: 11130419. DOI: 10.3389/fonc.2024.1399574.

References

Raza A, Sood G . Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014; 20(15):4115-27. PMC: 3989948. DOI: 10.3748/wjg.v20.i15.4115. View

Peng B, He Q, Li J, Zhou F . Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009; 198(3):313-8. DOI: 10.1016/j.amjsurg.2008.09.026. View

Yu M, An T, Li J, Chang D, Zhang Z, Xiao Y . Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. J Vasc Interv Radiol. 2021; 32(8):1194-1202. DOI: 10.1016/j.jvir.2021.03.540. View

Bruix J, Takayama T, Mazzaferro V, Chau G, Yang J, Kudo M . Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16(13):1344-54. DOI: 10.1016/S1470-2045(15)00198-9. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

. [Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)]. Zhonghua Gan Zang Bing Za Zhi. 2022; 30(4):367-388. DOI: 10.3760/cma.j.cn501113-20220413-00193. View

Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G . Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery?. World J Gastroenterol. 2021; 27(21):2784-2794. PMC: 8173387. DOI: 10.3748/wjg.v27.i21.2784. View

He C, Wu T, Hao Y . Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun. 2018; 503(4):3093-3099. DOI: 10.1016/j.bbrc.2018.08.098. View

Zhang Y, Chen M, Chen Y, Lau W, Peng Z . Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. JAMA Netw Open. 2021; 4(9):e2126992. PMC: 8477266. DOI: 10.1001/jamanetworkopen.2021.26992. View

10.

Lin Z, Lu D, Wei X, Wang J, Xu X . Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. Am J Cancer Res. 2020; 10(4):1085-1102. PMC: 7191099. View

11.

Galle P, Finn R, Qin S, Ikeda M, Zhu A, Kim T . Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(7):991-1001. DOI: 10.1016/S1470-2045(21)00151-0. View

12.

Kim M, Kim B, Kim S, Park J, Ahn S, Han K . Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol. 2019; 54(10):1283-1290. DOI: 10.1080/00365521.2019.1673478. View

13.

Li Q, Cao M, Lei L, Yang F, Li H, Yan X . Burden of liver cancer: From epidemiology to prevention. Chin J Cancer Res. 2023; 34(6):554-566. PMC: 9829497. DOI: 10.21147/j.issn.1000-9604.2022.06.02. View

14.

Han C, Ye S, Hu C, Shen L, Qin Q, Bai Y . Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Front Oncol. 2021; 11:684867. PMC: 8313824. DOI: 10.3389/fonc.2021.684867. View

15.

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

16.

Gelli M, Sebagh M, Porcher R, Romanelli E, Vibert E, Sa Cunha A . Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. Ann Surg. 2020; 272(5):820-826. DOI: 10.1097/SLA.0000000000004259. View

17.

Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R . Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol. 2015; 12(8):481-9. DOI: 10.1038/nrclinonc.2015.78. View

18.

Tsai I, Wang C, Yu T, Lu Y, Lin C, Lu L . Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine. 2016; 90:54-59. DOI: 10.1016/j.cyto.2016.10.007. View

19.

Chen X, Li W, Wu X, Zhao F, Wang D, Wu H . Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Front Oncol. 2022; 12:909035. PMC: 9197581. DOI: 10.3389/fonc.2022.909035. View

20.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View